Acelyrin, Inc. Class Action Lawsuit - SLRN

The filed complaint alleges that Acelyrin, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) izokibep, the Company's lead product candidate, was less effective in treating Hidradenitis Suppurativa than defendants had led investors to believe; (ii) accordingly, Acelyrin overstated izokibep’s clinical and/or commercial prospects; (iii) as a result, Acelyrin also overstated the Company’s business prospects post-initial public offering; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

In order to be eligible to join the SLRN class action lawsuit, you must have incurred a loss on shares of Acelyrin purchased during the class period listed above.

If you suffered a loss in Acelyrin during the relevant time frame or pursuant to the relevant offering(s), you have until January 16, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.